REFERENCES
J. Rak, B. St. Croix, and R. Kerbel. Consequences of angiogenesis for tumor progression, metastasis, and cancer therapy.Anticancer Drugs 6:3-18 (1995).
J. Folkman. What is the evidence that tumors are angiogenesis dependent? J.Natl.Cancer Inst. 82:4-6 (1990).
N. Ferrara and T. David-Smith. The biology of vascular endothelial growth factor. Endocr.Rev. 18:4-22 (1997).
S. Eppler, E. R. McCluskey, T. D. Henry, M. Simons, F. J. Giordano, and T. F. Zioncheck. Unique kinetics and hemodynamics of vascular endothelial growth factor (rhVEGF) following intracoronary and intravenous infusion in humans. J.Am.Col.Cardiol. 35:73A-74A (2000).
H. P. Gerber, J. Kowalski, D. Sherman, D. A. Eberhard, and N. Ferrara. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res. 60:6253-6258 (2000).
L. G. Presta, H. Chen, S. J. O'Connor, V. Chisolm, Y. G. Meng, L. Krummen, M. Winkler, and N. Ferrara. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57:4593-4599 (1997).
N. E. Simister, I. E. Jacobowitz, J. C. Ahouse, and C. M. Story. New functions of the MHC class I-related Fc receptor, FcRn. Biochem.Soc.Trans. 25:481-486 (1997).
Y. S. Lin, C. Nguyen, J. L. Medoza, E. Escandon, D. Fei, Y. G. Meng, and N. B. Modi. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J.Pharmacol.Exp.Ther. 288:371-378 (1999).
K. J. Kim, B. Li, J. Winer, M. Armanini, N. Gillett, H. S. Phillips, and N. Ferrara. Inhibition of vascular endothelial growth factorinduced angiogenesis suppresses tumour growth in vivo. Nature 362:841-844 (1993).
E. Bergsland, H. Hurwitz, L. Fehrenbacher, N. J. Meropol, W. F. Novotny, J. Gaudreault, G. Lieberman, and F. Kabbinavar. A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial growth factor) plus 5-fluorouracil/leucovorin (FU/LV) to FU/LV alone in patients with metastatic colorectal cancer. PASCO 19:242a (2000).
R. F. DeVore, L. Fehrenbacher, R. S. Herbet, C. J. Langer, K. Kelly, J. Gaudreault, E. Holmgren, W. F. Novotny, and F. Kabbinavar. A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. PASCO 19:485a (2000).
M. S. Gordon, K. Margolin, M. Talpaz, G. W. Sledge Jr., E. Holmgren, R. Benjamin, S. Stalter, S. Shak, and D. C. Adelman. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J.Clin.Oncol. 19:843-850 (2001).
B. Q. Shen, D. Y. Lee, H. P. Gerber, B. A. Keyt, N. Ferrara, and T. F. Zioncheck. Homologous up-regulation of KDR/Flk-1 receptor expression by vacular endothelial growth factor in vitro. J.Biol.Chem. 273:29979-29985 (1998).
J. Liu, P. Lester, S. Builder, and S. J. Shire. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry 34:10474-10482 (1995).
J. A. Fox, T. E. Hotaling, C. Struble, J. Ruppel, D. J. Bates, and M. B. Schoenhoff. Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in Cynomolgus monkeys. J.Pharmacol.Exp.Ther. 279:1000-1008 (1996).
M. Schoenhoff, D. Bate, J. Ruppel, D. Fei, J. A. Fox, D. Thomas, and P. Jardieu. Pharmacokinetics/dynamics following administration of a recombinant humanized monoclonal anti IgE antibody in cynomolgus monkeys. J.Allergy Clin.Immunol. 95:356 (1995).
H. Milgrom, R. B. Fick, J. Q. Su, J. D. Reimann, R. K. Bush, M. L. Watrous, and W. J. Metzger. Treatment of allergic asthma with monoclonal anti-IgE antibody. N.Engl.J.Med. 341:1966-1973 (1999).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hsei, V., DeGuzman, G.G., Nixon, A. et al. Complexation of VEGF with Bevacizumab Decreases VEGF Clearance in Rats. Pharm Res 19, 1753–1756 (2002). https://doi.org/10.1023/A:1020778001267
Issue Date:
DOI: https://doi.org/10.1023/A:1020778001267